ArticleThe Journal of experimental medicine2020

Targeting CLK3 inhibits the progression of cholangiocarcinoma by reprogramming nucleotide metabolism.

Qingxin Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.